We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for West Pharmaceutical's (WST) Q2 Earnings?
Read MoreHide Full Article
West Pharmaceutical Services, Inc. (WST - Free Report) is set to report second-quarter 2020 results on Jul 23, before the market opens.
In the last reported quarter, the company reported an earnings surprise of 23.17%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, with the average being 17.99%.
Let’s take a look at how things have shaped up prior to this announcement.
Factors at Play
West Pharmaceutical, during first-quarter earnings call in April, confirmed that it registered an upsurge in customer orders for its products, with the growing intensity of the pandemic. Riding on this uptrend, the company’s performance in the beginning of the second quarter was strong and this is likely to have boosted the top line.
Robust organic sales in the first quarter due to strong high-value product sales of the Proprietary Products suite are likely to have continued in the second quarter as well, in turn significantly contributing to revenues. The company maintained its guidance for organic sales growth at 8% compared with the prior expectation of 7-8%.
West Pharmaceutical Services, Inc. Price and EPS Surprise
The company observed during the second quarter that it was presented with new opportunities from companies looking to develop COVID-19 solutions. This is likely to have generated more sales for the company in the second quarter and driven the top line.
Persistent collaborations with biotech and biopharma customers who are using West Pharmaceutical's and Daikyo's high-value product offerings are likely to have favored the stock in the to-be-reported quarter. The company’s Biologics market unit is anticipated to have continued its strong performance in the second quarter as well.
In the first quarter, the Generics market unit saw strength on robust sales of Westar and FluroTec components. The Pharma market unit was driven by sales of high-value products and services including Westar, NovaPure and FluroTec components. Contract Manufacturing’s strong organic sales growth was led by sales of diagnostic and health care-related injection systems. The momentum of the three units is likely to have continued in the second quarter and significantly boosted the top line.
For the full year, the company maintained its view for net sales in the range of $1.95 billion-$1.97 billion. Notably, the net sales guidance includes an estimated full-year headwind of $26 million for full-year 2020 based on current foreign exchange rates compared with the prior expectation of $15 million.
West Pharmaceutical now projects 2020 adjusted earnings per share within $3.52-$3.62 compared with the earlier guidance range of $3.45-$3.55. The EPS guidance includes an estimated headwind of 7 cents based on current foreign currency exchange rates compared with the prior projection of 4 cents.
Notably, the revised guidance includes a 7 cents EPS impact from first-quarter tax benefits from stock-based compensation. For the rest of the year, the EPS guidance assumes a tax rate of 24% and does not include potential tax benefits from stock-based compensation.
The Estimate Picture
The Zacks Consensus Estimate for second-quarter 2020 revenues is pegged at $493.2 million, indicating growth of 5% from the year-ago reported figure. The same for the bottom line is 88 cents per share, suggesting fall of 1.1% from the year-ago quarter.
What Our Model Suggests
Our proven model does not conclusively predict an earnings beat for West Pharmaceutical this time around, The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, this is not the case here as you will see below.
Zacks Rank: The company currently carries a Zacks Rank #2.
Earnings ESP: West Pharmaceutical has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks Worth a Look
Here are a few medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.
Exact Sciences Corporation (EXAS - Free Report) has an Earnings ESP of +23.14% and a Zacks Rank of 2 at present.
Thermo Fisher Scientific Inc. (TMO - Free Report) has an Earnings ESP of +14.37% and is a Zacks #1 Ranked stock.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
What's in Store for West Pharmaceutical's (WST) Q2 Earnings?
West Pharmaceutical Services, Inc. (WST - Free Report) is set to report second-quarter 2020 results on Jul 23, before the market opens.
In the last reported quarter, the company reported an earnings surprise of 23.17%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, with the average being 17.99%.
Let’s take a look at how things have shaped up prior to this announcement.
Factors at Play
West Pharmaceutical, during first-quarter earnings call in April, confirmed that it registered an upsurge in customer orders for its products, with the growing intensity of the pandemic. Riding on this uptrend, the company’s performance in the beginning of the second quarter was strong and this is likely to have boosted the top line.
Robust organic sales in the first quarter due to strong high-value product sales of the Proprietary Products suite are likely to have continued in the second quarter as well, in turn significantly contributing to revenues. The company maintained its guidance for organic sales growth at 8% compared with the prior expectation of 7-8%.
West Pharmaceutical Services, Inc. Price and EPS Surprise
West Pharmaceutical Services, Inc. price-eps-surprise | West Pharmaceutical Services, Inc. Quote
The company observed during the second quarter that it was presented with new opportunities from companies looking to develop COVID-19 solutions. This is likely to have generated more sales for the company in the second quarter and driven the top line.
Persistent collaborations with biotech and biopharma customers who are using West Pharmaceutical's and Daikyo's high-value product offerings are likely to have favored the stock in the to-be-reported quarter. The company’s Biologics market unit is anticipated to have continued its strong performance in the second quarter as well.
In the first quarter, the Generics market unit saw strength on robust sales of Westar and FluroTec components. The Pharma market unit was driven by sales of high-value products and services including Westar, NovaPure and FluroTec components. Contract Manufacturing’s strong organic sales growth was led by sales of diagnostic and health care-related injection systems. The momentum of the three units is likely to have continued in the second quarter and significantly boosted the top line.
For the full year, the company maintained its view for net sales in the range of $1.95 billion-$1.97 billion. Notably, the net sales guidance includes an estimated full-year headwind of $26 million for full-year 2020 based on current foreign exchange rates compared with the prior expectation of $15 million.
West Pharmaceutical now projects 2020 adjusted earnings per share within $3.52-$3.62 compared with the earlier guidance range of $3.45-$3.55. The EPS guidance includes an estimated headwind of 7 cents based on current foreign currency exchange rates compared with the prior projection of 4 cents.
Notably, the revised guidance includes a 7 cents EPS impact from first-quarter tax benefits from stock-based compensation. For the rest of the year, the EPS guidance assumes a tax rate of 24% and does not include potential tax benefits from stock-based compensation.
The Estimate Picture
The Zacks Consensus Estimate for second-quarter 2020 revenues is pegged at $493.2 million, indicating growth of 5% from the year-ago reported figure. The same for the bottom line is 88 cents per share, suggesting fall of 1.1% from the year-ago quarter.
What Our Model Suggests
Our proven model does not conclusively predict an earnings beat for West Pharmaceutical this time around, The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, this is not the case here as you will see below.
Zacks Rank: The company currently carries a Zacks Rank #2.
Earnings ESP: West Pharmaceutical has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks Worth a Look
Here are a few medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.
Integra LifeSciences Holdings Corporation (IART - Free Report) has an Earnings ESP of +20.69% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Exact Sciences Corporation (EXAS - Free Report) has an Earnings ESP of +23.14% and a Zacks Rank of 2 at present.
Thermo Fisher Scientific Inc. (TMO - Free Report) has an Earnings ESP of +14.37% and is a Zacks #1 Ranked stock.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>